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NEUROPILIN 2 EXPRESSION AND FUNCTION IN 
MELANOCYTES AND MELANOMA 
SALVATORE RIZZO 
ABSTRACT 
Neuropilin 2 (NRP2) is a transmembrane protein receptor originally discovered in 
neurons, and their precursors, neural crest cells (NCC), which are a transient, migratory 
precursor population derived from neural ectoderm.  NRP2 serves as both a vascular 
endothelial growth factor (VEGF) co-receptor to initiate a pro-angiogenic signaling 
cascade and as a receptor for the class 3 semaphorin family molecules (primarily 
SEMA3F).  Binding of SEMA3F induces a strong repulsive and antiangiogenic signal.  
NRP2 was discovered on melanocytes, which was a novel finding.   NRP2-positive 
melanocytes were first identified in the hair follicles of Nrp2+/gfp transgenic mouse model.  
It is known that melanocytes reside in the bulb of the hair, where they provide pigment.  
Melanocyte stem cell populations are found in the bulge, a superficial structure also 
containing keratinocyte precursors.  NRP2 has also been suggested as a potential 
biomarker in cases of malignant melanoma.  The aim of this study was to elucidate the 
role of NRP2 three areas: in the growth and development of hair, in melanocytes, and in 
malignant melanoma. A greater understanding of the role of NRP2 in these locales may 
have significant clinical significance in disease states such as alopecia, vitiligo, and 
melanoma.  It was discovered that Nrp2 expression was strongest within the bulge region 
of the hair follicle where melanocyte stem cells reside. Additionally, human and mouse 
primary melanocytes express NRP2, whereas keratinocytes do not. Neither melanocytes 
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nor melanoma express VEGFR2, indicating NRP2 may be serving as a SEMA3F 
receptor.  The NRP2 receptor was functional in melanocytes as treatment with SEMA3F 
inhibited migration of both melanocytes and melanoma cultured lines. Melanoma cells 
downregulate expression of SEMA3F and upregulate the expression of NRP2. In the 
patient samples analyzed, the expression of NRP2 correlated with disease progression.  
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INTRODUCTION 
 
The Neuropilins: A Brief Comparison 
Neuropilin (human: NRP; mouse: Nrp) is a transmembrane receptor glycoprotein, 
with a molecular weight between 130 and 140 k-Da (Bielenberg et al., 2006).   
Neuropilin 1 was first discovered in the midbrain of a frog 1987 by Fujisawa (Takagi et 
al., 1987), and was shortly thereafter found to exist in several other neuronal tissue across 
multiple species (Kawakami et al., 1995; Takagai et al., 1995).  Neuropilin 2 was 
discovered a decade later by two independent labs (Chen et al., 1997; Kolodkin et al., 
1997).  The domain structure of NRP2 is identical to that of NRP1, and both share 45% 
base pair homology.  The genes for the two molecules are located on separate 
chromosomes in humans and in mice, however, with NRP1 found on chromosome 10 and 
NRP2 on chromosome 2 (Klagsbrun, Takashima, & Mamluk, 2002).  The two molecules 
have similar extracellular domains (a1/a2, b1/b2, and c), transmembrane and cytoplasmic 
domains (Chen et al., 1997).   
 
Figure 1 | Structure of NRP: NRP in both mouse and human is composed of three binding 
domains, a transmembrane domain, and a cytoplasmic domain ending in the SEA motif. From 
Panigrahy et al., 2014. 
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Each of the three extracellular domains binds different ligands.  The a1/a2 domain 
is the primary receptor for the class 3 semaphorin (SEMA3) family molecules, while the 
b1/b2 domain acts as a co-receptor for Vascular Endothelial Growth Factor (VEGF) 
binding.  The c domain serves as a locale for NRP:NRP dimerization.  The intracellular 
domain consists of a relatively short, 40 amino acid sequence.  NRP1 and NRP2 share 
55% homology in this domain, but both terminate in the same serine, glutamic acid, 
alanine (S-E-A) sequence (Bielenberg et al., 2006).  This terminal sequence has been 
shown to interact with a cytoplasmic protein called neuropilin interacting protein (NIP), 
although no signaling pathway has been discovered associated with this interaction (Cai 
& Reed, 1999).  Recent studies have shown that deletion of this SEA sequence in NRP1 
disrupts Placental Growth Factor (PlGF) signaling in medulloblastoma lines, suggesting 
that the cytoplasmic domain may indeed have an important, if yet undiscovered, function 
(Snuderl et al., 2013).   
Several isoforms of neuropilin 2 exist, all of which arise from alternative splicing 
of the NRP2 exons (Chen et al., 1997).  In addition, there are soluble forms of NRP’s 
which may act as competitors for SEMA3 and VEGF binding (Rossignol, Gagnon, & 
Klagsbrun, 2000).   
Ligands of Neuropilin 2: the Semaphorin Family 
 The first ligand of NRP was discovered in 1997 to be the semaphorin class III 
(SEMA3) family of molecules (Kolodkin et al., 1997).  There are over 20 SEMA genes 
producing eight known classes of semaphorins, and the molecules are organized 
according to their structure and evolutionary origin.  The class 3 family are the only 
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secreted semaphorins and there are seven members of the SEMA3 family, designated A-
G.  The seven molecules have similar molecular weights (approximately 100kDa) and are 
the only members of the semaphorin tree found to bind to NRP (Worzfeld & Offermanns, 
2014).  SEMA3 molecules bind two domains on NRP.  The highly conserved “sema” 
region binds to the a1a2 domain, while the carboxy-terminus binds to the b1b2 domain of 
NRP (Bielenberg & Klagsbrun, 2007).   The binding specificities of the members of the 
SEMA3 family relative to the neuropilins are as follows: SEMA3A only binds to NRP1, 
and SEMA3F and SEMA3G bind specifically and with high affinity to NRP2.  The 
remaining SEMA3 molecules (save SEMA3E) can bind either NRP1 or NRP2 
(Klagsbrun & Shimizu, 2010).  In the context of SEMA3, both NRP1 and NRP2 act as 
essential coreceptors for their respective SEMA3 molecules; that is, the SEMA3/NRP 
complex is not sufficient to activate downstream signaling cascades (Puschel, 2002).  In 
order to initiate a signaling cascade, SEMA3/NRP must also bind the primary 
semaphorin signaling family of receptors, the plexins.  Of primary significance is the 
NRP2/SEMA3F relationship, which signals through Plexin A1 in both cancerous cells 
and in endothelial cells (EC) (Shimizu et al., 2008). SEMA3E is unique in that it does not 
require a NRP coreceptor, but rather binds directly to its receptor, Plexin D1, where it can 
initiate the signaling cascade (Gu et al., 2005; Klagsbrun & Shimizu, 2010). 
 SEMA3F is a potent inhibitor of cell migration, reflective of its role as a guidance 
molecule.  Several studies have demonstrated the inhibitory effects of SEMA3 on EC 
proliferation (Shimizu et a., 2008; Acevado et al., 2008).  Additionally, it may have a 
critical role in angiogenesis and cancer metastasis as an angiogenesis inhibitor.  For 
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example, A375SM melanoma cells transfected with SEMA3F demonstrated decreased 
adhesion and motility, while cell proliferation remained unaffected (Bielenberg et al., 
2004)  Additional studies suggest that the lack of adhesion and motility is due to the 
inhibitory effects of SEMA3F on Beta1 Integrin (Bielenberg et al., 2004).  SEMA3F may 
also act to collapse f-actin stress fibers, effectively preventing cell membrane 
rearrangement and consequently, cell movement (Shimizu et al., 2008; Bielenberg et al., 
2008).   
Ligands of Neuropilin 2: VEGF 
The second important ligand of NRPs is the VEGF family, a well-known group of 
molecules, particularly in the field of angiogenesis.  VEGF has been described as a potent 
inducer of endothelial cell proliferation and migration, and well as a strong pro-
angiogenic and permeability factor (Dvorak et al., 1995).  The proteins are approximately 
20 kDa, but are functionally active as dimers (Ferrara, 1996).  The principal form of 
VEGF, VEGF-A, is subject to alternative splicing and post-translational modification 
yielding four distinct isoforms: VEGF121, VEGF165 (the most common isoform), 
VEGF189, and VEGF206 (Klagsbrun & D’Amore, 1996).  The VEGF family can bind one 
of two classes of receptors, the neuropilins and the receptor tyrosine kinase (RTK) VEGF 
Receptor (VEGFR) family, which consists of VEGFR1 (FLT-1), VEGFR2 (KDR), and 
VEGFR3 (FLT-4).  The VEGFR receptors are tyrosine kinase receptors, with the 
dimerization and autophosphorylation typical of such receptors.  The three VEGFR have 
different affinities for the various members of the VEGF family.  VEGFR1 binds VEGF-
A, -B, and PlGF, another member of the VEGF family.  VEGFR2 binds VEGF-A, -C, -D, 
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and –E.  VEGFR3 binds VEGF-C and VEGF-D (Ruiz de Almodovar et al., 2009).  
VEGFR2 is considered the primary regulator of VEGF-induced cell migration and 
proliferation due to its greater tyrosine kinase activity compared to the other two VEGFR 
(Ferrara et al., 2003).  
The second family of receptors that bind VEGF are the neuropilins.  Unlike the 
VEGFR family, binding to NRP by VEGF is not necessary or sufficient to induce an 
intracellular signaling cascade.   Instead, NRP acts as a coreceptor for VEGFR2 
(angiogenic) and VEGFR3 (lymphangiogenic), amplifying the response to ligand binding 
(Soker et al., 2001; Favier et al., 2006)(Figure 1).  NRP1 associates with VEGF-A, -B, 
and –E.  NRP2 binds VEGF-A, -C, and –D (Klagsbrun et al., 2002; Gaur et al., 2009).   
 
Figure 2 | Neuropilin 2 and its Ligands: The two ligand families of neuropilin 2 (SEMA3 and 
VEGF) are shown above, along with their respective primary receptors.  The lines between the 
free molecules and NRP2 demonstrate the binding sites for each.  The C domain on NRP2 is used 
for dimerization (not shown). 
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Neuropilin 2 Physiologic Expression 
 While the neuropilins were initially discovered on neuropiles (hence the name), 
subsequent studies have revealed a much more robust expression throughout the body 
(Gagnon et al., 2000; Wild et al., 2012).  Despite their similarities in structure, the two 
neuropilins are differentially expressed throughout the body, though their expression is 
not necessarily mutually exclusive.  NRP are differentially expressed on neural crest 
(NC) cells, contributing to the polarity and location of these cells (Ruhrberg & Schwartz, 
2010; Theveneau & Mayor, 2012).  For another example, in the nervous system NRP2 is 
restricted to sympathetic neurons while NRP1 is found on both sympathetic and sensory 
neurons (Bagri & Tessier-Lavigne, 2002).  Both neuropilins are expressed on endothelial 
cells.  In the blood vasculature, NRP2 is clearly expressed in veins, while NRP1 is 
restricted to arteries during development, and while this definitive demarcation is lost in 
the mature organism, NRP2 is still heterogeneously expressed in capillaries, veins, and 
lymphatics (Herzog et al, 2001; Bielenberg et al., 2006).  While expression of NRP2 is 
variable among lymphatic vessels, there is no evidence of NRP1 expression on these 
vessels (Yuan et al., 2002).   
The neuropilins are not restricted to only migratory and guidance functions.  
NRP1 has a demonstrated function in the immune system, serving as a mediator for 
dendritic cell (DC)-T cell interactions.  Inhibition of this interaction abolishes the DC-
dependent T cell proliferation (Tordjman et al., 2002).  Both NRPs have been found on 
leukocytes and macrophages as well, though complete comprehension of their role is still 
to be determined (Stepanova et al., 2007; de Paulis et al., 2006).   
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NRP2 is also expressed in developing bone and in visceral smooth muscle 
(particularly in the bladder and intestine) (Chen 1997; Bielenberg et al., 2012).  NRP2 
has also been implicated in bone homeostasis, as loss of Nrp2 results in trabecular bone 
loss mediated by enhanced osteoclast activity coupled with a decreased osteoblast 
population (Verlinden et al., 2013).  While the mechanism of NRP2 function in many 
tissues is still yet to be determined, its extensive expression throughout the body’s tissues 
hints at its significance in normal physiological function. 
Nrp2 Transgenic Mice 
 Yuan et al. were the first to describe the lymphatic phenotype of transgenic Nrp2 
knockout mice in the early 21st century.  They found that while viable into adulthood, 
homozygous Nrp2 mutant mice demonstrated a severe reduction of small lymphatic 
vessels and capillaries in the heart, lung, skin, and other tissues examined.  This 
malformation of lymphatic capillaries was found to be due to a reduction in Nrp2 protein 
synthesis, and not from other factors like improper folding of the protein (Yuan et al., 
2002).  Interestingly, the Nrp2 knockout mice are not edematous.  Heterozygotes express 
a phenotype similar to wild type mice.  Homozygous mutant Nrp2 offspring are found to 
be present at a lower than expected Mendelian frequency, both in Yuan’s experiments 
and during the current study. Later studies involving double knockout genetic lines for 
NRP2/VEGFR3 (the primary receptor for VEGF-C) demonstrated the importance of 
proper NRP2 function in lymphangiogenesis , and has hinted at a key role in cancer 
metastasis (Xu et al., 2010).  Additionally, mice lacking Nrp2 demonstrate a marked loss 
in neuronal function, particularly in cranial nerve, spinal sensory axon, and hippocampal 
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mossy fiber axon development (Chen et al., 2000).  As mentioned previously, SEMA3F 
is critical for the proper migration of axons and NC cells, and these malformations can 
likely be attributed to lack of functional SEMA3F mediated repulsion. 
 The Bielenberg laboratory houses two lines of transgenic mice.  The Nrp2+/gfp 
transgenic mice have a Green Fluorescent Protein (GFP) insert after exon 1, functionally 
“knocking in” GFP while “knocking out” Nrp2.  The endogenous Nrp2 promoter remains 
untouched and functionally active, resulting in expression of GFP in place of endogenous 
Nrp2 in vivo.  Thus, the GFP serves as a read-out of Nrp2 expression.  Nrp2gfp/gfp 
(knockout) mice are viable through adulthood.  Adult homozygous knockout mice are 
smaller in size than their wild-type littermates, although the heterozygotes display no 
noticeable difference in gross appearance.  The second line of transgenic mice is the 
Nrp2+/LacZ mice, which serve a similar function as the GFP line; the LacZ protein is 
expressed in lieu of endogenous Nrp2.  Like the GFP mice, the LacZ mice have an insert 
after exon 1 encoding the beta-galactosidase (LacZ) gene while maintaining the original 
Nrp2 promoter.  Thus, LacZ is expressed in vivo in lieu of endogenous Nrp2.  Staining 
with X-gal reagent reveals the location of LacZ; GFP must be observed with fluorescent 
microscopy.  Unlike the GFP knock-in mice, however, Nrp2LacZ/LacZ mice are not viable 
and perish at birth for unknown reasons. 
The Melanocyte 
 The skin can be divided into three distinct layers: the epidermis, the dermis, and 
the subcutaneous tissue.  The cells of the skin are constantly exposed to a variety of 
damaging external conditions and carcinogens from which it needs protection.  One of 
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these carcinogens is ultraviolet (UV) radiation, typically originating from the sun.  UV 
radiation causes the formation of cyclobutane pyrimidine dimers in the DNA of exposed 
cells, and mutations accumulate when this damage is not repaired (Berneburg & 
Krutmann, 2000).  Melanocytes, a small minority of specialized cells in the epidermis, 
confer protection to neighboring cells (primarily keratinocytes) from UV radiation 
through production and distribution of melanin, a photoprotective pigment (Tandler, 
Mosch, & Pietzsch, 2012; Lang et al., 2013).  In the skin, melanocytes are typically found 
along the basal layer of the epidermis, where they are anchored to the basement 
membrane of the epidermis (Thingnes et al., 2012).   
 
Figure 3 | Melanocyte and Melanocyte Stem Cell Development: Both melanocytes and 
melanocyte stem cells (McSc) originate from melanoblasts derived from Neural Crest (NC) cells.  
Mature melanocytes proliferate and populate the epidermis, as well as the bulb of hair follicles.  
McSc reside in the bulge and migrate to the bulb at the beginning of a new hair cycle, where they 
differentiate into melanocytes as the new hair begins to grow. From Li et al., 2014. 
Melanocytes originate during development from the ectoderm-derived neural 
crest, and migrate and differentiate into three distinct subpopulations (Uong & Zon, 
2009).  Trunk neural crest cells (NC cells) can progress through either of two pathways: 
the ventral pathway (forming neuronal tissue) and the dorsolateral pathway (giving rise to 
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melanoblasts, the precursor cells of melanocytes) (Serbedzija et al., 1990).  These 
melanoblasts then migrate to their final destinations before differentiating into mature 
melanocytes or melanocyte stem cells (McSc) (Figure 2) (Li, 2014).  NC cells migration 
is directed by a variety of environmental cues, which repel NC cells from forbidden 
locations and allow the colonization in appropriate locales (Theveneau & Mayor, 2012).  
One of these repellents is Semaphorin.  NC cells express the semaphorin receptors, the 
neuropilins, which aid in NC cell migration (Lumb et al., 2014).   
In addition to forming the aforementioned cutaneous melanocytes, melanoblasts 
also migrate to the hair follicle and the iris (Boissy, 1988).   In the hair follicle, mature 
melanocytes are localized in the bulb, where they secrete melanin into the matrix of the 
hair.  McSc are found in the bulge, a structure superficial to the bulb (Li, 2014).   
Hair Cycle 
 The animal model of interest is the murine model.  Thus, it is important to note 
the differences between the murine and human skin and hair cycle.  Both mouse and 
human consist of the same three layers of skin (epidermis, dermis, and hypodermis) and 
adhere to a morphologically similar defined cycle of hair growth and loss (Wong et al., 
2011; Kligman, 1959).  The three stages are as follows: anagen, catagen, and telogen 
(Figure 3).  The anagen phase is characterized by rapid growth of the hair follicle due to a 
robust blood supply (Muller-Rover et al., 2001).  In the catagen phase, the hair follicle 
regresses, driven by keratinocyte apoptosis (Lindner et al., 1997).  The final phase, 
telogen, is a resting stage characterized by relative quiescence and lack of a blood supply 
to the follicle (Muller-Rover et al., 2001).  Where human and mouse differ in regards to 
	  	  11 
these stages is in the timing.  In mice, the coat of hair progresses sequentially through the 
hair cycle in wavelike manner from cranial to caudal; in humans, each hair cycles 
individually, so that three hairs picked at random may be in three different stages of 
growth (Wong et al., 2011).  Upon depilation, the hair cycle in mice resets, and all 
depiled follicles will start the cycle anew in sync (Muller-Rover et al., 2001). 
	  
Figure 4 | The Murine Hair Cycle: The hair cycle consists of three phases, a) anagen, b) 
catagen, and c) telogen.  Melanocytes are lost during catagen and are replaced by McSc during 
the telogen phase. Murine hair cycles through this process in waves, moving cranial to caudal; 
human hair cycles on an individual basis.  Removal of the hair follicle starts the cycle anew. 
Taken from Muller-Rover et al., 2001. 
Neuropilin 2 Pathologic Expression 
The extensive physiological expression of neuropilin is mirrored in pathological 
conditions, particularly in cancer.  The first reported tumors expressing neuropilin were 
the PC3 prostate and MDA-MB-231 breast cancer cell line (Soker et al., 1998).  Since 
then, many types of tumors have been shown to express at least one neuropilin, although 
it is not uncommon to observe dual expression.  Generally, carcinomas express higher 
levels of NRP1; NRP1 has been found in bladder, pancreatic, renal, colon, ovarian, and 
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lung carcinomas (Wey, Stoeltzing, & Ellis, 2004; Neufeld et al., 2005; Bielenberg et al., 
2006)(Figure 4).   
 
Figure 5 | Expression of NRP in Various Human Cancers: The above PCR demonstrates the 
differing expression of both NRPs in various human cancer cell lines.  Expression is not mutually 
exclusive, but a clear trend emerges between the two.  NRP1 is highly expressed in carcinomas, 
while NRP2 is favored by cancers of neural crest derived cells.  Cell lines used for RT-PCR (from 
left to right): PC3, MDAMB231, 253JB5, SN12PM6, A375SM, U87MG, Sy5Y, HUVEC.  From 
Bielenberg et al., 2006 
Reflecting their physiological expression, NC derived tissues and sarcomas 
upregulate NRP2 (Bielenberg et al., 2006).  One exception to the non-carcinoma-NRP2 
guideline is pancreatic ductal adenocarcinoma (PDAC), which highly expresses NRP2.  
Normal pancreatic ductal cells do not express any NRP1 and only lowly express NRP2 
(Fukahi et al., 2004).   
The discovery of NRP in so many tumors has raised questions into its potential 
role in cancer.  Early research on malignant prostate carcinoma biopsies showed a 
marked upregulation of NRP1 when compared to normal prostate tissue (Miao et al., 
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2000).  These samples were negative for VEGFR, but displayed classic signs of 
angiogenesis, including high VEGF levels and increased vessel density.  This finding 
ruled out the possibility of autocrine VEGF signaling, while simultaneously positing a 
function for NRP.  The VEGF sequestration hypothesis suggests that NRP may be 
binding VEGF not to initiate a signaling cascade, but rather to act as a reservoir.  In this 
way, the tumor is able to achieve higher total VEGF concentration in the tumor 
microenvironment than would be possible if the VEGF was free.  This VEGF–rich 
environment then promotes angiogenesis (Miao et al., 2000).  NRP2-expressing tumors 
may act in the same manner, in addition to promoting lymphangiogenesis.  A study 
conducted in 2008 further hints at the importance of NRP in tumors.  NRP2 knockdown 
in PDAC was achieved using shRNA (Dallas et al., 2008).  Without NRP2, the PDAC 
cells displayed a 70% decrease in migration and a similar reduction in invasion and in 
vivo growth capabilities; proliferation in vitro was unaffected.  These NRP2 knockdown 
tumors in vivo were up to 95% smaller than the control tumors and exhibited significant 
decreases in blood vessel diameter (Dallas et al., 2008).  These data demonstrate that 
direct inhibition of NRP2 can inhibit tumorigenicity and progression, as well as tumor-
induced angiogenesis. 
Additionally, it is known that in many types of cancer, the increased expression of 
NRP2 or the downregulation of SEMA3F correlates with tumor progression (Bielenberg 
et al., 2004).  Studies have demonstrated the important role the SEMA3F-NRP2 
relationship has in cancer.  SEMA3F mRNA levels were found to be decreased in highly 
metastatic tumors relative to those cell lines with lower metastatic potential, both in vitro 
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and in vivo (Bielenberg et al., 2004).  When A375SM cells transfected to overexpress 
SEMA3F were implanted in vivo, the resulting tumors were found to have large voids 
consisting of apoptotic cells in the center of the mass.  SEMA3F transfected tumors also 
showed an inability to metastasize to lung and lymph node, while 21/22 control mice had 
tumors in those locations.  SEMA3F induces an encapsulated tumor phenotype and 
inhibits tumor angiogenesis, characteristic of benign neoplasms, demonstrating its 
clinical potential as an anti-tumor agent (Bielenberg et al., 2004).  
The Origin of a Cancer Cell 
 Cancer cells originate from the accumulation of abnormal characteristics in the 
body’s own cells.  Healthy cells must accumulate at least six essential malignant 
characteristics before the devastatingly limitless dividing capabilities of a tumor can be 
unlocked.  The “Hallmarks of Cancer” first outlined by Hanahan & Weinberg at the turn 
of the century defined these “acquired capabilities” a cell needs to obtain in order to 
transform into a malignant tumor cell (Figure 5).  It may take many generations of cells 
before enough mutations accumulate to transform a benign cell into a malignant one, and 
these features need not be obtained sequentially.  In addition, the mechanisms by which 
cells acquire these malignant capabilities may vary between from tumor to tumor.  All 
requirements must be satisfied if a tumor is to develop, however, let alone metastasize 
(Hanahan & Weinberg, 2000). 
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Figure 6 | Acquired Capabilities of Tumor Cells: The six hallmarks of cancer cells, as 
described by Hanahan & Weinberg.  A tumor, not necessarily one cell, must acquire these traits 
in order to become truly malignant.  The tumor at the center depicts this heterogeneous 
composition of a tumor.  Taken from Hanahan & Weinberg, 2000. 
 In physiologic conditions, a cell must receive an external growth signal input in 
order to progress from a quiescent state to a mitotically active one.  While normal cells 
cannot proliferate without these stimulatory signals, tumor cells have freed themselves 
from the influence of exogenous signaling. This may be accomplished by altering the 
external signal itself, by a mutation in the receptor for the signal, or by modifying the 
signaling pathway of the receptor, among others (Hanahan & Weinberg, 2000). Not every 
tumor cell in the neoplasm needs to act by the same mechanism.  There is also evidence 
that a thriving tumor is composed of several unique malignant subpopulations, rather than 
of one continuously dividing clone.  Thus, the tumor microenvironment is heterogeneous, 
not homogenous (Fidler, 2003).  Furthermore, the tumor architecture is complex and 
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often differs remarkably from the surrounding tissue (both normal and neoplastic) 
(Heppner, 1984).  These two facts are important to consider when discussing the 
development and progression of any tumor.  For example, one subpopulation can evolve 
a mutation to produce Fibroblast Growth Factor (FGF) when it should not; neighboring 
tumor cells that lack the capability to produce FGF may take up this tumor-derived 
growth factor for its own survival and proliferation (Jouanneau et al., 1994). 
 Tumor cells similarly are able to liberate themselves from regulation by inhibitory 
anti-growth signals.  Cells in healthy tissue are subject to such signals, which arrest the 
cell in the non-proliferative phase (G0), returning them to or maintaining quiescence.  The 
inactivation of tumor-suppressor genes (e.g. SEMA3F), an area of great research, is one 
method by which tumor cells can accomplish this (Hanahan & Weinberg, 2000).  
Another highly productive field of research focuses on the ability of malignant cells to 
evade normal signals for apoptosis; the process is highly regulated primarily by the 
caspase family of proteins (Khan et al., 2014).  Caspase dysregulation, among other 
mechanisms (i.e. p53 inactivation) is highly prevalent among malignant cancers 
(Hanahan & Weinberg, 2000).  In addition to the regulatory cellular signals mentioned 
above, every cell has finite number of replicative divisions, regulated by the repetitive 
nucleotide sequences at each end of the chromosome called telomeres.  These sequences 
serve to protect the DNA from deterioration during mitosis.  Tumor cells, however, are 
able to grant themselves infinite reproductive capabilities.  Telomerase, normally inactive 
in mature cells, is reactivated in tumor cells, contributing to their increased mitotic 
abilities (Blasco, 2002; Hanahan & Weinberg, 2000).  There is also evidence that it is 
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possible to obtain this limitless dividing potential even without the activation of 
telomerase (Seger et al. 2002).  The final two acquired capabilities a tumor must obtain 
are sustained angiogenesis and tissue invasion, both of which will be discussed at greater 
length below. 
Physiological and Pathological Importance of Angiogenesis 
 One of the most important organ systems of the body, the vascular system is 
typically a stable and quiescent tissue.  The unit of this system, the endothelial cell (EC), 
lines all blood and lymph vessels.  Under normal physiologic conditions EC’s rarely 
divide (Folkman 1974).  Under certain physiologic and pathologic conditions, however, 
EC’s can proliferate remarkably, forming new vessels for the body’s fluids.  This process 
of neovascularization is called angiogenesis (Auerbach & Auerbach, 1994).  More 
specifically, angiogenesis is the formation of new vessels from previously existing ones, 
as opposed to vasculogenesis, which is the creation of new vessels from angioblasts, the 
mesoderm-derived progenitor cells of the endothelium (Noden, 1989).  Angiogenesis is 
vital during growth and proliferation of the body’s normal tissues, i.e. during 
development of the fetus and embryo, and abnormal tissues, i.e. tumors (Chung, Lee, & 
Ferrara, 2010).  This fact is important both in understanding the development of the 
human body and the growth and eventual metastasis of tumors. 
 Physiological and pathological (specifically tumor) angiogenesis are similar in 
that both begin in response to hypoxia associated proteins like Hypoxia Inducible Factor 
1 alpha (HIF1α) and VEGF, often in response to ischemia.  Nevertheless, there are 
several important distinctions to note.  Under physiological conditions, the signals 
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promoting angiogenesis subside once the hypoxic tissue has been perfused.  Tumor 
neovasculature persists even in normoxic conditions, however, largely due to the aberrant 
production of pro-angiogenic factors by tumor cells (Chung, Lee, & Ferrara, 2010). 
 There is a limit to the maximum size of an avascular tumor, i.e. one that has not 
developed its own blood supply.  The seminal paper by Dr. Judah Folkman noted that this 
distance is approximately 1–2 mm.  Without adequate blood supply, tumor cells cannot 
thrive.  In addition to its importance in tumor survival, angiogenesis is an essential step in 
the process of tumor metastasis (Folkman, 1971).    
The Angiogenic Process 
 In both physiologic and pathologic conditions, angiogenesis begins with EC 
response to hypoxia.  In response to low oxygen (O2) concentration, cells upregulate 
expression of HIF1α, which in turn upregulates expression of VEGF-A and vascular 
endothelial growth factor receptor 2 (VEGFR-2).  VEGF-A is a potent stimulator of 
angiogenesis (Chung, Lee, & Ferrara, 2010).  The increased binding and signaling of 
VEGF-A leads to the selection and migration of the tip cell, a highly polarized and 
specialized EC.  This tip cell is the beginning of the new vessel, and other EC proliferate 
(stalk cells) and migrate behind it (Gerhardt et al., 2003).  In order to progress through 
the extracellular matrix (EM), the tip cell and stalk cells must secrete matrix 
metalloproteases (MMP), proteins which serve to degrade the surrounding collagenous 
basement membrane.  This degradation of EM proteins by MMP’s allows the growing 
vessel stalk to migrate up the gradient of growth factors into the perivascular stroma 
(Effert & Strohmeyer, 1995).  It is important to note that throughout this process, the 
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endothelium is kept intact.  Distal cell migration is supported by proliferation of the 
proximal EC, ensuring that the fluids of the vessel are always contained.  Following 
migration and proliferation, the endothelium undergoes reorganization to form a mature 
capillary (Auerbach & Auerbach, 1994).   
 Angiogenesis is a tightly regulated process in normal tissue involving a complex 
interplay between proangiogenic and antioangiogenic molecules (Hanahan & Folkman, 
1996).  A surplus of proangiogenic molecules encourages the local formation of new 
blood vessels; a surplus of angiogenesis inhibitors prevents the development of new 
vessels.  This sensitive balance can be tipped in one direction or the other by a variety of 
molecules.   Pathological conditions, like a hypoxic cell or a tumor microenvironment, 
can introduce a variety of angiogenesis promoters like fibroblast growth factor (FGF), 
vascular endothelial growth factor (VEGF), angiopoietin (Ang-1, Ang-2), platelet-
derived growth factor (PDGF), transforming growth factor alpha and beta (TGF-α, TGF-
β), and interleukin-8 (IL-8), to name a few (Longo, 2012).  Introduction of these 
molecules, possibly in conjunction with a downregulation of antiangiogenic factors like 
semaphorin (SEMA), endostatin, angiostatin, or thrombospondin may also contribute to 
the generation of an imbalance in the angiogenic switch, kickstarting the process of 
neovascularization (Ribatti, 2009; Wang et al., 2015).   
The Process of Cancer Metastasis 
 Metastasis is a complex biological process, consisting of many interrelated steps.  
At each step exists the possibility of failure, and a single misstep can derail the entire 
process.  In 2003, Fidler equated a successful metastatic cell to “a decathlon champion 
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who must be proficient in all ten events, rather than just a few” (Fidler, 2003).  A 
successful metastasis depends not only on the correct characteristics of the tumor cells 
(“the seed”), but also on an accommodating environment of the target tissue (“the soil”) 
(Paget, 1889).  There are two primary avenues for tumor metastasis: through the 
cardiovascular vessels or through the lymphatic vessels.  Regardless of entry method, 
tumor cells must reach the blood circulation before settling in a novel organ (Tobler & 
Detmar, 2006).  Robert Weinberg proposed a seven step process necessary for the 
metastasis (Valastyan & Weinberg, 2011).  These steps were developed with the 
progression through the blood vasculature of epithelial-derived tumors, or carcinomas, in 
mind.  The seven steps are as follows (Figure 6): 
1. Local invasion of the tumor, first by breaking through the basement 
membrane and then spreading into the stroma, often as a result of MMP 
upregulation 
2. Intravasation of tumor cells into the lumen of blood vessels and/or lymphatic 
vessels of the stroma, frequently as a result of neoangiogenesis 
3. Survival in the blood and lymphatic circulation, which exposes the tumor cells 
to a wider spectrum of tissues 
4. Arrest at a distant organ site, whereby the tumor cell(s) adhere to the wall of 
the vessel; this typically occurs in the microvasculature, i.e. capillary beds 
5. Extravasation into the parenchyma of distant organ  
6. Initial survival in the foreign microenvironment and subsequent 
micrometastasis formation 
7. Proliferation of micrometastases, progressing to colonization of the new organ 
or tissue 
	  	  21 
 
Figure 7 | The Process of Cancer Metastasis: Tumor cells (in red) must embark on a complex 
and difficult journey before appearing as a clinically detectable metastasis.  Cells must invade the 
nearby tissue for access to a blood supply. If this supply is reached, tumor cells must then 
intravasate and survive in the systemic circulation.  Once the cells arrive at a suitable site (often 
the capillary bed of a distant organ), they must extravasate and successfully evade the host 
defenses long enough to colonize the new organ.  Taken from Fidler et al., 1998. 
After observing these guidelines, Weinberg concluded that metastasis is an inefficient 
process (Valastyan & Weinberg, 2011).   
While still inefficient, metastasis via the lymphatic system may be slightly easier 
than in its counterpart system.  In fact, for many tumor types, the lymphatic system is the 
primary mode of dissemination. Certain inherent differences between lymphatic vessels 
and cardiovascular vessels may explain why tumor cells move more freely through the 
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lymphatic system.  Lymphatic capillaries are characterized by a wider and more irregular 
lumen than their cardiovascular counterparts, have incomplete or non-existent BM, have 
fewer tight junctions and adherens junctions between the endothelial cells lining the 
lumen, and are more tightly associated with the adjacent interstitial tissue (Leak, 1970).   
Taken together, these characteristics of lymphatic vessels may result in a 
truncated version of the stepwise process of metastasis outlined above.  For example, 
intravasation from the vessel is not necessarily required in for tumor cells in the 
lymphatic circulation (Sleeman, 2000).  Instead, tumor cells in the lymphatic system may 
enter the bloodstream after colonizing a nearby lymph node (via the efferent lymphatic 
vessels) or through the thoracic and right lymph ducts, which return lymph to the 
systemic circulation (Tobler & Detmar, 2006).  Metastasis may be inefficient, but it still 
accounts for 90% of deaths associated with solid tumors like melanoma (Gupta & 
Massague, 2006).   
Lymphangiogenesis and Metastasis 
 As noted above, angiogenesis is necessary for a tumor to grow larger than 1–2mm 
in diameter, which roughly translates to 106 cells.  The proliferation of vessels is usually 
associated with a tumor that metastasizes to secondary sites in the body.     
Lymphangiogenesis is to lymphatic vessels as angiogenesis is to blood vessels; 
that is, both processes result in the formation of new vessels from previously existing 
ones.  The lymphatic system is a blind-ended network of vessels that serves to drain the 
interstitium of excess fluid, and works in concert with the immune system to provide an 
efficient system of lymphocyte transportation and surveillance (Swartz & Skobe, 2001).  
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Lymph is moved through the vessels by several, primarily local, means.  Pressure arising 
from the interstitium (both hydrostatic pressure and mechanical strain of the ECM) and 
contraction of neighboring skeletal muscle are the most prominent sources of driving 
force.  Additionally, the larger lymphatic collecting vessels are enveloped by smooth 
muscle cells and like veins, contain valves. Unfortunately, lymphatic vessels also provide 
tumor cells with an alternate route for migration, and one that is often used in clinically 
assessing the metastatic potential of the tumor (Swartz & Skobe, 2001). 
 It is well known that tumors secrete pro-lymphangiogenic factors, which in turn 
provide the growing tumor with access to a larger lymphatic network (Stacker et al., 
2002).  In addition to these growth factors, tumor lymphangiogenesis also depends on the 
tumor’s anatomical location.  Tumors derived from tissues that are naturally closer to 
smaller lymphatic vessels, which are more lymphangiogenic, demonstrate a greater 
affinity for metastasis than those farther away (Shayan et al., 2013).  Lymphatics 
associated with tumors and tumor cell metastasis are most likely to derive from small 
lymphatics.  For example, a melanoma with a higher ratio of peripheral to centrally-
located lymphatic vessels is more likely to metastasize than one with a lower ratio 
(Shayan et al. 2013).    
The Development and Progression of Melanoma 
 Tumors arising from melanocytes are called melanomata (singular: melanoma).  
Together, melanomata account for 5% of all malignant skin cancers, but compromise a 
stunning 90% of skin cancer deaths (Tandler, Mosch, & Pietzsch, 2012).  While primary 
tumors are easily excised, melanomata that have progressed and spread are not so 
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successfully treated, primarily due to the resistance of the tumors to chemotherapeutic 
and radiotherapeutic agents (Uong & Zon, 2009).  Due to this, early identification and 
treatment of a melanoma is critical in ensuring positive outcomes.  Risk factors include 
family history, a fair complexion, and exposure to UV radiation, particularly having had 
multiple severe sunburns in childhood (Lo & Fisher, 2014).     
 Melanomas must progress through the previously outlined steps in order to 
achieve malignancy and metastasis, but also encounter another hurdle along the path to 
malignancy.  Melanocytes are normally subject to regulation by keratinocytes and must 
escape this control in order to progress through the stages of cancer (Haass & Herlyn, 
2005).  This is accomplished through a five step molecular process, outlined below. 
1) Downregulation of E-cadherin, P-cadherin, and desmoglein, which connect 
melanocytes and keratinocytes 
2) Upregulation of Mel-CAM, N-cadherin, and other proteins that allow for 
melanoma cell-melanoma cell and melanoma cell-fibroblast communication 
3) Deregulation of morphogens, which regulate cell fate 
4) Downregulation of basement membrane anchoring proteins 
5) Increased production of MMP 
Once melanomata have freed themselves from control by keratinocytes (and have 
accumulated the requisite hallmarks of cancer), they then begin to progress through a 
series of well-defined stages (Laga & Murphy, 2010) (Figure 7).  The first step in the 
process is abnormal proliferation of noninvasive, nontumorigenic cells.  This initial 
growth eventually proliferates and expands radially through the epidermis.  This is called 
the radial growth phase and is rarely metastatic.  The third step in the progression is 
characterized by a propensity for vertical growth, which often presents superficially as an 
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elevated growth on the skin.  The transition from the radial growth phase to the vertical 
growth phase correlates with VEGF accumulation and increased protein expression in the 
tissue surrounding the tumor (Streit & Detmar, 2003).  More importantly, however, is the 
deep growth of the tumor and its subsequent breaching of the basement membrane.  This 
third development, called the vertical growth phase, is necessary for the progression to 
the final step, metastasis to distant lymph nodes and organs (Laga & Murphy, 2010).   
 
Figure 8 | Progression of Melanoma: Melanomata progress through a series of distinct stages.  
The tumor grows first radially, then vertically, before it penetrates the basement membrane.  
Here, it has access to the blood and lymph vessels needed for successful metastasis.  Once the 
tumor has metastasized, it is exceedingly lethal. From Melanoma New Zealand 
(melanoma.org.nz) 
 
Clinically, this process is identified and labelled according to the system 
developed by Alexander Breslow, eponymously named the Breslow depth.  Increased 
Breslow depth correlates to a greater likelihood of metastases, and consequently a worse 
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prognosis (Breslow, 1970).  Perhaps not coincidentally is the finding that NRP2 
expression levels correlate with Breslow depth and increases from nevi to primary 
melanomas to metastases.  Other measures have been shown to have more clinical 
relevance however.  Tumor lymphatic vessel density is a better predictor of metastasis 
than Breslow depth (Dadras & Detmar, 2004).  Unsurprisingly, an increase in NRP2 
expression correlates with probability of developing the metastatic disease.  Expression 
of NRP2 mRNA was found to be higher in thicker melanomas than in thin tumors, 
implicating NRP2 as a potential biomarker for malignant melanoma (Rossi et al., 2014).  
 Primary tumor location has a significant influence on the metastatic potential of a 
tumor.  In one study, murine tumors located in the skin metastasized more readily than 
those growing in the body wall. This occurred due to the natural anatomic access a tumor 
growing in the skin has to smaller lymphatic vessels, which have greater 
lymphangiogenic potential.  This fact explains the tendency for melanomata to travel via 
the lymphatic system versus the cardiovascular system (Shayan et al., 2013). Due to the 
high metastatic potential of melanoma, and the difficulty in treating the tumor once it has 
metastasized, the identification of a biomarker that can accurately and precisely discern 
between those tumors with high vs. low metastatic potential would be revolutionary in 
the management of the disease.   
 This study hopes to elucidate the physiological role of NRP2 in melanocytes, 
where it may function as a regulator of migration, and pathological location of NRP2 in 
melanoma. In melanoma, the upregulation of NRP2 accompanied with a decrease in 
SEMA3F concentrations may play a role in tumor growth and progression. 
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METHODS 
 
Cell Culture 
 Human epithelial melanocyte cells (neonate) (HeMn) were purchased from 
Cascade. SKMel28 human melanoma cells, A2058 human melanoma cells, and WM266-
4 human melanoma cells were purchased from American Type Culture Collection. 
MMAN human melanoma cells and A375SM human melanoma cells were obtained from 
Isaiah Fidler (MD Anderson Cancer Center, Houston, TX).  Human keratinocytes 
(HaCaT) were obtained from Michael Detmar (Switzerland), and human fibroblasts 
(Milo) were obtained from Deborah Freedman (Boston Children’s Hospital).  Once 
thawed, using a 37°C water bath, the cells were deposited in 100mm culture plates 
accompanied by 10mL of media.  Each cell line requires a different medium to flourish.  
The media used were as follows: RPMI (MelaC), Medium 254 (HeMn), DMEM (all 
melanoma lines, HaCaT, milo).  Each medium was supplemented with 10% Fetal Bovine 
Serum (FBS) and 1% glutamine-penicillin-streptomycin (GPS).  Once plated, cells were 
incubated in humidified 37°C incubators at the appropriate CO2 concentrate (either 5% or 
10%).  Media was aspirated and replaced every three days.  Once plates reached 
approximately 90% confluence, the cells were assigned one of several fates based on the 
needs of the lab at the time.   
 If no current experiments required new cells, the confluent plate would be split 
into two or more new 100mm plates.  Media was aspirated and the cells were washed 
with 3mL 0.05% trypsin ethylenediaminetetraacetic acid (EDTA).  Once the trypsin was 
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applied, plates were incubated for five minutes to maximize effectiveness of the trypsin.  
At the conclusion of this period, plates were struck by hand several times to loosen cells 
from the bottom of the plate.  After confirming via microscope that cells had lifted off the 
plate, the trypsin was neutralized using either trypsin neutralizing solution (TNS)(Gibco) 
or, most often, fresh media containing serum.  Cells were added to as many new plates as 
desired (1mL suspended cells per new plate) and once again incubated. 
Protein Isolation 
 The second course of action for a nearly confluent plate was to lyse the cells in 
order to isolate and collect protein.  This following process was carried out on ice or in a 
cold environment for as many steps as possible.  This was accomplished by first 
removing the media and washing the plate with phosphate buffered saline (PBS).  PBS 
was removed and 500µL protein lysis buffer was added.  Protein lysis buffer was created 
by dissolving one ULTRA mini tablet protease inhibitor in 10mL radio immune 
precipitation assay (RIPA) buffer (Roche).  Plates were scraped using a specialized sterile 
tool and the liquid was collected in an aliquot.  After allowing the tube to rest for 20 min 
(on ice), the tube was centrifuged at 14,000 rpm for 10 min.  This resulted in a pellet 
accruing at the bottom of the tube.  Supernatant was collected and frozen in a new, 
labeled aliquot, and the pellet was discarded.   
Protein Analysis 
 Cell lysates were analyzed via the VERSAmax microplate reader (Molecular 
Devices) at a wavelength of 575nm.  Samples require a specific preparation protocol 
before they could be analyzed accurately.  For each sample, two 5µL aliquots were 
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pipetted into a 96 well plate.  A Bovine Serum Albumin (BSA) standard was serially 
diluted and pipetted in triplicate alongside the lysate samples.  Next, 20µL Protein Assay 
Solution S (Bio-Rad) was added to 1mL Protein Assay Solution A (Bio-Rad).  25µL of 
this A+S solution was added to each well containing lysate or standard to be tested.  
Finally, 200µL Protein Assay Solution B (Bio-Rad) was added to the same wells that 
received the A+S solution.  Once each well was prepared, samples were allowed to rest at 
room temperature for five minutes before being read by the VERSAmax reader.  The 
standard readings and their known concentrations were plotted in a line graph using 
Microsoft Excel and a best fit formula was calculated.  This formula was then used to 
calculate the protein concentrations of each experimental sample. 
Casting the SDS-Page Gel 
 All Western blots were gels created by the same formula, which is as follows.  
The resolving layer, which separates the protein in each sample, was made by mixing 
3.75mL of 30% acrylamide/0.8% bis-acrilamyde (National Diagnostics) with 3.75mL 4x 
1.5M tris-HCL/0.4% SDS pH 8.8 (resolving buffer) (National Diagnostics), 7.5mL sterile 
double distilled water, 50µL 10% ammonium persulfate (APS), and 10µL 
tetramethylethylethylenediamine (TEMED).  The stacking layer, which condenses each 
sample so as to ensure an even run across samples down the resolving layer, was made by 
mixing 0.65mL acrylamide/0.8% bis-acrilamyde (National Diagnostics) with 1.25mL 
0.5M tris-HCl/0.4% SDS pH 6.8 (stacking buffer) (National Diagnostics), 3.05 mL sterile 
double distilled water, 25µL APS, and 5µL TEMED.  The resolving layer was pipetted 
first into a casting mold (Bio-Rad) and consequently topped with a thin layer of methanol 
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to eliminate any bubbles.  This ensured a level, uninterrupted surface onto which the 
stacking layer was placed.  After approximately thirty minutes, once the resolving layer 
had polymerized, the methanol was poured out and the stacking layer added.  For each 
layer, the TEMED was introduced immediately before pipetting into the mold.  A ten 
well comb measuring 1.5mm in thickness was inserted into the still-liquid stacking layer.  
Any bubbles that may have formed between the teeth of the comb were removed.  Once 
the gel had polymerized, it was removed from the plastic cast and either was used 
immediately or wrapped in damp paper towels and saran wrap to be stored at 4°C.   
Running the Western Blot 
 Based on the previously run protein analysis, cell lysate samples were diluted 
accordingly with distilled water.  Each sample was diluted such that there was 36µg of 
protein per well.  A colored protein ladder was including alongside the samples for 
molecular weight reference.  In addition to the cell lysate and water, each well also 
contained 5µL 6x-reducing SDS Sample Buffer.  All samples (including the reference 
ladder) were boiled for five minutes and centrifuged prior to loading.  While the samples 
were boiling, the SDS-Page gels were submerged in 1X running buffer (25mM Tris, 
192mM glycine, 0.1% SDS, pH 8.3), and the ten well comb was removed.  Salt was 
removed from the wells by pipetting running buffer into the submerged well until clear.  
Once the samples were prepared, the protein ladder and each sample was loaded in its 
entirety into a unique well, with care taken to record the identity of each sample.  The lid 
was connected to the apparatus and to the power supply.  Gels were allowed to run at 
100V for two hours.  
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 Following separation by electrophoresis, proteins were similarly allowed to 
transfer to a nitrocellulose membrane (Bio-Rad).  The gel/membrane was then submerged 
in 1X transfer buffer (25mM Tris, 192mM glycine, pH 8.4) and subjected once again to 
electrophoresis.  The apparatus was allowed to run overnight at 4°C and 75mA or for two 
hours on ice and at 300 mA.   
 Once the transfer was complete, the gels were discarded, and Ponceau S solution 
(Sigma) was introduced to the nitrocellulose membrane to ensure a successful transfer.  
Ponceau was removed by washing with Tris Buffered Saline (10 mM Tris-HCl, 150mM 
NaCl, pH 7.4) with 1% Tween-20 (TBS-T).  The membrane was then blocked with 5% 
blotting-grade blocker non-fat dry milk (Bio-Rad) in TBS-T for one hour at room 
temperature.  After blocking, the membrane was rinsed once briefly with TBS-T.  The 
primary antibody was prepared using anti-NRP2 antibody (H-300, Santa Cruz) at a 
1:1000 ratio in TBS-T.  The membrane was then incubated with the primary antibody for 
two hours at room temperature with mild agitation.  Following primary antibody 
incubation, the membrane was again washed with TBS-T (3x15 min).  Horseradish 
peroxidase (HRP) conjugated anti-rabbit antibody was used as the secondary antibody at 
a concentration of 1:3000.  The secondary antibody solution was added to the membrane 
and allowed to incubate for one hour with agitation at room temperature.  Once again, the 
membrane was washed with TBS-T three times for fifteen minutes each after secondary 
antibody incubation.  An enhanced chemiluminescence (ECL) solution was prepared by 
mixing Oxidizing Reagent with Enhanced Luminol Reagent from the Western Lighting 
Plus-ECL kit (Perkin Elmer) in a 1:1 ratio.  The solution was poured on the membrane, 
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which was allowed to rest at room temperature for five minutes before being placed in a 
cassette for transportation to the dark room for exposure.  Initially the membrane was 
exposed for one minute, and the exposure time was increased or decreased as needed.  
Migration Assays 
 Cells were trypsinized and removed from culture.  Each cell sample was spun 
down in a centrifuge for five minutes at 1000 rotations per minute.  After centrifuging, 
the existing media was aspirated and replaced with the appropriate serum-free media.  In 
order to count the cells, 10 µL of suspended cells in serum-free medium was loaded into 
a hemocytometer.  The hemocytometer is then observed with light microscopy at 100x 
magnification.  Cells are counted in the four demarcated corner squares, making sure to 
only count cells on the lines of two sides of the square.  This ensures that no cell is 
counted twice.  The average count for the four squares is then multiplied by 10,000 to 
obtain the density of cells in suspension, measured in cells/mL.  Once the cells have been 
counted, the migration plate is prepared. 
 The migration plate used is a standard 24 well plate with twelve plastic inserts.  
At the bottom of each insert is an 8-micron pore cell-permeable membrane.   An 
assembled migration apparatus consists of two wells separated by the barrier.  The 
bottom well was filled with 600 µL of culture medium with 10% FBS.  In the top well, 
the suspended cells were plated in known quantity.  In the SEMA3F experiment, the 
SEMA3F was added to the top chamber at graduated concentrations.  The inserts (and 
suspended cells) were placed in the bottom wells, ensuring that no bubbles were present 
between the two chambers.  The entire 24-well plate was then placed in the incubator for 
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sixteen hours. 
 After allowing sufficient time for the cells to migrate, the 24 well plate was 
removed from the incubator.  The top well inserts were removed and each one was fixed 
and stained with the DiffQuik kit.  First, each insert was placed in a fixative for five 
minutes.  Once fixed, the inserts were placed in the first staining solution for five minutes 
and a second staining solution for ten minutes.  After fixing and staining, the inserts were 
allowed to rest in double distilled water for five minutes.  At the end of this wash, the 
cells remaining inside the insert (i.e. those that did not migrate) were removed with 
cotton swab.  The inserts were observed under a light microscope at 200x magnification 
and the cells were counted. Eight fields were averaged for each condition. 
Immunohistochemisry 
 Formalin fixed, paraffin embedded (FFPE) tissue sections were submerged in 
xylene (first for four minutes, then for three) in order to remove the paraffin.  The tissue 
was then progressively rehydrated by means of a six step ethanol ladder, consisting of 
two immersions in 100% ethanol, two in 95% ethanol, one in 70% ethanol, and finally 
one in 50% ethanol.  Each submergence in the ethanol ladder lasted two minutes.  
Antigen retrieval was performed if necessary; the exact methods varied based on the 
primary antibody used.  For NRP2, antigen retrieval consisted of submersion in 10mM 
sodium citrate buffer, pH 6, and heated for five minutes in a microwave.  Once citrate 
reached a temperature of 95°C, the microwave was turned off and the tissue was allowed 
to cool gradually in citrate until it reached approximately 50°C.  Slides stained for S100β 
required no antigen retrieval.  Once the tissue had cooled to a safe temperature for 
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handling, each slide was removed from the citrate buffer and a hydrophobic ring was 
drawn around each sample with a pap pen.  Each slide was washed with 3 times for 3 
minutes per wash with PBS.  To block endogenous peroxidase activity, and to promote 
permeability of the tissue, 3% hydrogen peroxide in methanol was added to the tissue and 
allowed to incubate at room temperature for 12 minutes.  Following the peroxide block, 
each section was once again washed with PBS (3 x 3 min).  Tissues were then subjected 
to a protein block using Tris-NaCl blocking buffer (TNB) for at least thirty minutes.  
Primary antibody was then pipetted to the slides at the appropriate concentration (in 
TNB) and allowed to incubate at 4°C overnight. 
 The subsequent day, slides were washed of primary antibody (3 x 3min) with PBS 
before application of the corresponding biotinylated secondary antibody.  Secondary 
antibody was also prepared in TNB at a concentration of 1:200 and, once applied to the 
slide, allowed to incubate for one hour at room temperature.  After this step, the signal 
was amplified using an Avidin/Biotinylated Enzyme Complex (ABC) kit (Vector).  This 
step required preparation of the solution in PBS at least thirty minutes before application.  
Before application of the ABC solution, the slides were washed with PBS (3 x 3min).  
DAB Chromagen Kit (Vector) was prepared in distilled water and was used to detect 
bound antibody.  Prior to addition of chromagen, the slides were washed one last time, 
twice with PBS (3 min each) and once with distilled water (3 min).  DAB was then 
applied and allowed to incubate at room temperature for up to twenty minutes.  Brown 
precipitate, indicating a bound antibody and thus a positive result, was observed using 
light microscopy.  After 20 minutes, the sections were washed with distilled water and 
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counterstained with hematoxylin and Tacha’s Bluing Solution (BioCare Medical), which 
turned the counterstain blue instead of purple.  Slides were allowed to dry overnight 
before being mounted the next day with Permount (Fisher). 
Mice 
 Mice were housed in a pathogen-free environment in the Boston Children’s 
Hospital animal facility, which is accredited by the Association for Assessment and 
Accreditation of Laboratory Animal Care (AAALAC). The standards and regulations set 
forth by the US Department of Agriculture, Department of Health and Human Services, 
NIH, and the Institutional Animal Care and Use Committee (IACUC) of Boston 
Children’s Hospital were carefully followed at all times when handling the animals.  
 The primary genetic line of interest was the previously purchased Nrp2+/gfp line of 
transgenic mice (Nrp2+/gfp/MomJ, Stock #006700).  The mice were bred to yield viable 
homozygous knockouts, which were used to elucidate the physiological location and 
function of Nrp2. 
 After three weeks of age, mice were genotyped to determine its genetic 
classification.  First, ear samples were collected by anesthetizing the mice and removing 
the ear with sterile equipment.  The ears was placed on ice and observed under a 
fluorescent microscope.  The knock-in of GFP for Nrp2 allowed one to discern two 
subcategories of mice based on the presence of GFP in the hair follicles.  Wild-type (WT) 
mice had no knock-in of GFP and thus did not present with GFP positive hair follicles.  
Heterozygous (het) and knock-out (KO) both displayed green hair follicles, and as such, 
no conclusion could be drawn as to the identity of the mice belonging to this group.  The 
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ear samples of the GFP positive group were packaged and sent to the mail-order 
genotyping service Transnetyx, which returned PCR results within a week.   
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RESULTS 
 
Melanocytes Express NRP2 
 In order to test whether NRP2 was expressed in melanocytes, human epidermal 
melanocytes – neonate (HeMn) and murine melanocytes (MelaC) were cultured and 
lysed for analysis by western blot.  The samples were run through a 7.5% SDS-Page gel, 
transferred to a nitrocellulose membrane, and immunoblotted with specific antibody in 
order to quantify relative neuropilin 2 expression.  Based on these experiments, it was 
found that both human and murine melanocytes expressed NRP2, a novel finding.  
Human protein levels were detected using the Santa Cruz H300 antibody against NRP2, 
while murine samples were subjected to analysis with a rabbit polyclonal antibody for 
Nrp2 (D39A5) manufactured by Cell Signaling Technology.   
HeMn western blots were run with HaCaT (human keratinocytes) and milo 
(human fibroblasts) cell lines, representing the most common cells present in the skin.  
Porcine Aortic Endothelial cells transfected to overexpress NRP2 (PAE NRP2) or 
VEGFR2 (PAE KDR) were added as control lines.  Mouse primary melanocytes were run 
with mouse primary keratinocytes (MK) isolated from 3-day-old neonates in the 
Bielenberg lab and transformed mouse fibroblasts (NIH 3T3).  Malignant cell lines 
(B16F10 – a mouse melanoma, and EOMA – a mouse endothelioma) as well as control 
samples from mouse skin and brain were also run in the gel.  Neither human (HaCaT) nor 
mouse keratinocytes (MK), displayed any significant expression.  Interestingly, human 
and mouse fibroblasts were found to express NRP2 on western blot but not with IHC.   
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HeMn were also compared to five melanoma lines (A2058, A375SM, WM 266-4, 
SKMel 28, MMAN), each of which also was found to express NRP2 (Figure 8).  This 
finding was expected and confirms prior research (Bielenberg et al., 2004).  Equivalently, 
MelaC cells were run with B16F10 mouse melanoma cells, which also tested positive for 
Nrp2.   
 
 
Figure 9 | Melanocytes Express NRP2: a) Mouse primary melanocytes express Nrp2, as do 
fibroblasts and melanoma cells.  Keratinocytes do not, but this may be due to a loading error; b) 
human melanocytes express NRP2, as do human fibroblasts; c) all five human melanoma lines 
tested express NRP2. 
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Melanocytes do not Express VEGFR2 
 Neither Western blot nor immunohistochemistry can reveal the function of the 
protein of interest.  Additional experiments are needed in order to elucidate the protein’s 
function in vivo.  As mentioned previously, NRP2 is involved primarily in the binding for 
two ligands: VEGF and SEMA3F, and successful binding of VEGF (i.e. one leading to 
induction of signaling cascade) and NRP2 requires the presence of a VEGF receptor.  
The western blot membranes used previously for NRP2 testing were incubated with an 
antibody for VEGFR2, which binds NRP2 ligands VEGF-A and VEGF-C.  It was found 
that the HeMn did not express VEGFR2 on either of the two blots, even though the 
positive control cell line (PAE KDR) did.  Additionally, none of the five human 
melanoma lines displayed any VEGFR2 expression (Figure 9).   
 
Figure 10 | Neither Melanocytes nor Melanoma Express VEGFR2: Western demonstrating 
the lack of VEGFR2 by all cell lines except the positive control (PAE KDR).  NRP2 is shown as 
a loading control. 
MelaC cells did not test positive for VEGFR2 either, although this finding must 
be repeated on a blot with a control cell line present in order to consider this a true result.  
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This finding suggests that NRP2 is not acting as a VEGF coreceptor for either 
melanocytes or melanoma lines, but rather in some other capacity. 
Melanocyte Migration is Inhibited by the Presence of SEMA3F 
 In order to test whether NRP2 on melanocytes was in fact acting as a receptor for 
SEMA3F, the mouse melanocytes (MelaC), along with B16F10 melanoma cells, were 
subjected to a migration assay.  Cells were cultured and counted before plating on the 
migration wells.  First, it was necessary to determine the optimal number of cells required 
for observable migration.  Both cell lines were plated in duplicate for each condition; 
each line was tested at 10,000, 20,000, and 40,000 cells.  B16F10 cells showed 
meaningful migration starting at 20,000 cells, while MelaC cells required at least 40,000 
cells before any meaningful migration could be observed.  In order to minimize 
confounding variables, it was determined that 40,000 cells would be plated for both cell 
lines in the experimental condition. 
 The migration assay was run again, using 40,000 cells per well.  B16F10 cells and 
MelaC cells were once again plated in duplicate and assigned to one of four conditions: a 
control group, which received no treatment (plated in the same environment as the 
previous study), and three groups receiving some concentration of SEMA3F.   The 
SEMA3F groups were treated with 150ng/mL, 300ng/mL, or 600 ng/mL, which was 
administered in the top well after combining the top and bottom chambers.  After 16 
hours, the cells were stained and counted using ImageJ software.  It was determined that 
SEMA3F treatment significantly reduced migration of both melanocytes and melanoma 
cells when compared to the control group (Figures 10, 11). 
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Figure 11 | Melanoma Migration is Inhibited by SEMA3F: (top) Increased dose of SEMA3F 
resulted in decreased melanoma migration. (bottom) Images from the migration assay 
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Figure 12 | Melanocyte Migration is Inhibited by SEMA3F: (top) Increased dose of SEMA3F 
resulted in decreased melanocyte migration. (bottom) Images from the migration assay 
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Antibody Optimization 
 There are several NRP2 antibodies available on the market, and the Bielenberg 
laboratory is in possession of three of them: the C-9 antibody (Santa Cruz), an antibody 
from Sigma-Aldrich, and the H300 antibody (Santa Cruz).  In order to determine the 
optimal antibody for IHC, three formalin-fixed, paraffin-embedded (FFPE) slides known 
to contain NRP2 were deparaffinized and prepped for IHC.  All three were submerged in 
citrate buffer and heated to 95oC; this served to increase the amount of antigen available 
for antibody binding.  After primary antibody incubation (all at a 1:200 dilution), ABC 
amplification, and subsequent chromagen application, each slide was observed based on 
intensity and specificity of staining.  After this evaluation, it was determined that the 
H300 antibody was most effective.   
 Once the H300 antibody was chosen, it was necessary to determine the optimal 
dilution for IHC.  Four tissue samples were used at three different dilutions, with the last 
serving as a control.  It was determined that optimal dilution for the purposes of this 
study was 1:100. 
NRP2 Expression Correlates with Melanoma Progression 
 Fifty eight human samples were stained for NRP2 (Santa Cruz) and S100B.  
Samples were analyzed by light microscopy and given an overall score ranging from 1 to 
9.  To determine the overall score, each slide was judged on two factors, intensity of 
staining and area of staining and given a score from 1 to 3, with a score of 1 categorizing 
the lightly stained or smallest area stained, and a 3 signifying most intense staining or 
largest area stained.  The two scores were then multiplied to obtain the final overall score.  
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The intensity of NRP2 staining was compared to the intensity of S100 staining, and it was 
found that NRP2 expression correlated with melanoma progression.  Tumor cells in 
lymph nodes were most positive for NRP2, while nevi were the most lightly stained.  
Primary melanoma samples fell between these two extremes (Figure 12).   
 
 
Figure 13 | NRP2 Expression Correlates with Melanoma Progression: Samples taken from 
metastatic tumors display more intense staining of NRP2 than control (human nevi).  Primary 
melanoma samples fall between these two extremes. 
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DISCUSSION 
 The foundation of this study began with the genotyping of the transgenic mice 
models.  Once we discovered that hair follicles expressed NRP2, we wanted to know 
which cells were responsible.  The two primary cells of the hair are keratinocytes and 
melanocytes, and we believed the melanocytes accounted for the distinct pattern we 
observed, largely based on their NC cell origin.    
 Neuropilin 2 continues to be observed in novel tissues, and in many cases, its 
function remains unknown.  Only recently has its importance in its earliest known locales 
been elucidated, and much research is still needed to fully understand its physiologic and 
pathologic role.  The presence of NRP2 in melanocytes is a novel finding, and, taken 
together with the fact that these cells also lack VEGFR2, suggests that NRP2 is not acting 
as a VEGF coreceptor.  The “VEGF reservoir” theory that was described earlier is a poor 
conceptual fit for the melanocyte model, although it may have merit when considering 
the upregulation of NRP2 in the melanoma lines tested.  Thus, the most plausible theory 
is that which considers NRP2 a functional SEMA3F receptor for melanocytes, but why 
should these cells need a directing force?  Melanocytes are typically located at or near the 
basement membrane under normal conditions.  Non-proliferating melanocytes adhere and 
are anchored to the basement membrane, but proliferating melanocytes lose these 
adhering properties (Danen et al., 1996).  This loss of BM adhesion allows the 
melanocytes to migrate and weave dendrites through the neighboring keratinocytes 
(Haass & Herlyn, 2005).  It is known that keratinocytes mediate melanocyte growth via 
cell-cell interactions, primarily via E-cadherin, which is expressed on both melanocytes 
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and keratinocytes (Tang et al., 1994; Hsu et al., 1996) (Figure 13).   
 
Figure 14 | Melanocyte-Keratinocyte Interactions: Melanocytes downregulate a number of 
regulatory proteins during mitosis, resulting in freedom from keratinocyte control.  SEMA3F may 
play a supplemental role in maintaining keratinocyte influence over melanocytes through its 
receptor, NRP2.  Adapted from Haass & Herlyn, 2005. 
 
NRP2 may be another method by which keratinocytes can regulate the growth and 
migration of epidermal melanocytes.  It has been shown in other epithelial tissue that 
there is a stratification of SEMA3F production by the superficial keratinocytes.  In skin, 
this may serve to prevent melanocyte migration toward the surface of the skin (Figure 
15).   
 
Figure 15 | Expression of SEMA3F and NRP2 Varies in Bladder: SEMA3F is found in the 
outermost layers of the bladder epithelium, while NRP2 is found deeper in the tissue.  This layout 
may be mirrored in skin, where keratinocytes in the outer layers produce SEMA3F to contain 
NRP2-expressing melanocytes in the inner layers. From Bielenberg, unpublished. 
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SEMA3F may also restrict melanocytes from straying during proliferation, when 
melanocytic downregulation of BM adhering proteins.  Once melanocytes have 
completed mitosis, SEMA3F may act as a guiding force, repositioning melanocytes 
where they are most needed. 
In order to investigate effects of NRP2 on melanocytes in vivo, further testing can 
center around a transgenic mouse line.  The Jackson Laboratory (JAX) is in possession of 
a tyrosinase-cre mouse line; the cre lines are useful for selectively knocking out genes.  
Tyrosinase is the enzyme responsible for the production of melanin.  Therefore, a 
tyrosinase-cre mouse can be bred with the NRP2 flox transgenic line already housed by 
the Bielenberg laboratory to selectively knock out NRP2 in melanocytes.  In vivo studies 
could then be carried out on both wild type mice and those without NRP2-expressing 
melanocytes to further elucidate the role of NRP2.  Additionally, by breeding inducible 
tyrosinase-cre mice with NRP2 floxed mice, one can observe the potential effects of 
NRP2 loss of function after birth.  Knocking out NRP2 after birth may prevent 
compensatory measures from kicking in, allowing for a truer sense of the protein’s 
function.  This has already been done in the Bielenberg lab, knocking out NRP2 in the 
smooth muscle of the bladder (Bielenberg et al., 2012). Additionally, the Bielenberg lab 
has recently purchased SEMA3F KO mice, and future studies on melanocyte location and 
function can be pursued with this model. 
 Previous research on melanoma cells and VEGFR2 has yielded mixed results.  
Several studies detected VEGFR2 expression on melanomata, both by IHC and by 
Western blotting, with reports claiming as prevalence as high as 89% (Salven et al., 1997; 
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Gitay-Goren et al., 1993; Pisacane & Risio, 2005).  The results of this study run contrary 
to these findings, but are not novel.  Others have raised similar doubts about VEGFR2 
expression (Molhoek et al., 2011).  There are several plausible explanations for this lack 
of VEGFR2.  Rather than signal through the VEGF pathway, melanomata may use 
alternative growth pathways (like scatter factor for example).   Melanomata may 
sequester VEGF via NRP2, establishing a strong gradient that encourages angiogenesis 
(Figure 16).   
 
Figure 16 | VEGF Sponge Theory: Tumors expressing high levels of NRP2 (without concurrent 
VEGFR2 expression) may use NRP2 to sequester VEGF in tumor adjacent tissue. This creates a 
gradient of VEGF leading to the tumor, which promotes EC proliferation and angiogenesis. 
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Another possibility, which was explored recently with NRP1 and VEGFR2 on 
endothelial cells, is that the tumor expresses NRP2 in order to amplify VEGF signaling in 
nearby endothelial cells (Figure 17).  This trans complex (NRP2 on melanoma, VEGFR2 
on endothelial cells) can induce a signal and increase EC proliferation in tumor-adjacent 
tissue, inviting angiogenesis and subsequently metastasis (Koch et al., 2014).   
 
 
Figure 17 |Trans Signaling: A schematic of trans, or juxtacrine, signaling.  A tumor cells 
expressing NRP2 can amplify the response to VEGF by an adjacent EC, promoting further EC 
proliferation.  This is one alternative possibility to the function of NRP2 on melanomata. Taken 
from Miao & Klagsbrun, 2000. 
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During the course of this thesis, a paper was published indicating that NRP2 
mRNA levels correlate with disease progression (Rossi et al., 2014).  .  The results of this 
thesis not only confirm those found recently, but also confirm that protein expression is 
increased. Further studies are needed to elucidate the role (if any) of NRP2 in 
melanomata, and to determine whether NRP2 can serve as an accurate biomarker for 
more aggressive tumors.  A biomarker like this is greatly needed, as there is currently no 
reliable method for predicting which melanoma will metastasize. 
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